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Abstract Objective. Atrial fibrillation (AF) in type 2 diabetes mellitus (T2DM) has been little explored so far. 
However, there are several cardio metabolic risk factors for AF in T2DM patients, such as arterial 
hypertension, obesity or the metabolic syndrome. Our objective was to evaluate cardio metabolic risk factors 
for AF in T2DM patients. Methods. We studied the medical records of T2DM patients hospitalized in the 
Internal Medicine department of an emergency referral hospital in Bucharest, Romania. The study was 
observational, retrospective and carried out between January-June 2018. Results. The study group included 
221 T2DM patients (with a mean age of 68.65 ± 10.64, ranging between 37-93 years): 116 women (52.49%; 
with a mean age of 70.53 ± 10.69, ranging between 37-93 years) and 105 men (47.51%; with a mean age of 
66.57 ± 10.23, ranging between 38-91 years). 92 patients had AF (41.63%): 40 women (34.48%) and 52 men 
(49.52%). 180 patients (81.45%) were hypertensive: 103 women (88.79%) and 77 men (73.33%). 113 
patients (51.13%) had metabolic syndrome: 58 women (50.00%) and 55 men (52.38%). 77 patients (34.84%) 
were obese: 45 women (38.79%) and 32 men (30.48%). AF patients associated obesity in 26 cases (28.26%), 
hypertension in 73 cases (79.35%) and metabolic syndrome in 56 cases (60.87%). Conclusions. Out of the 
study group, 92 T2DM patients (41.63%) had AF, men being more likely to suffer from AF than women 
(p=0.0288). Hypertension affected 180 patients (81.45%) and in greater proportion women vs. men 
(p=0.0051). The metabolic syndrome and obesity were discovered in 113 patients (51.13%) and 77 patients 
(34.84%), respectively, with no significant differences in terms of gender. In our research, the highest cardio 
metabolic risk factors for AF in T2DM were hypertension (OR = 3.6675) and the metabolic syndrome (OR = 
3.3388). 
 
Keywords  diabetes mellitus, atrial fibrillation, hypertension, obesity, metabolic syndrome, risk 
factors. 
Highlights  Patients with type 2 diabetes mellitus are at increased risk of developing atrial fibrillation.   
 Hypertension, metabolic syndrome and obesity are important cardio metabolic risk 
factors for atrial fibrillation in patients with type 2 diabetes mellitus.    
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Introduction 
Out of the cardiac arrhythmias, atrial fibrillation (AF) 
is undoubtedly the most frequently encountered entity in 
clinical practice (1). The number of patients with AF has 
been growing steadily up to the point in which this 
disorder has become an epidemic: in 2030, more than 12 
million people will be affected by AF in the United States 
(1, 2).  
Age, male sex, type 2 diabetes mellitus (T2DM), 
obesity, hypertension, heart failure and metabolic 
syndrome are some of the risk factors involved in the 
development of AF (3-5). The relationship between 
T2DM and AF is complex and of particular interest. A 
recent Danish cohort study, conducted on 253.374 T2DM 
patients vs. 4.827.713 subjects without T2DM, has 
postulated that, in the development of AF, T2DM is an 
independent risk factor and that younger subjects with 
T2DM are at higher risk of AF vs. elderly T2DM subjects 
(6). 
The cardio metabolic risk factors for AF have been 
intensively studied in the past decade and particular 
attention has been paid to the metabolic syndrome. Many 
studies have shown conflicting results regarding the 
impact of the metabolic syndrome on AF development, 
with some suggesting that AF is rather linked to some 
components of the metabolic syndrome rather than to the 
metabolic syndrome itself (5). The metabolic syndrome, 
defined as the co-occurrence of several metabolic risk 
factors in a single patient, can be easily diagnosed in a 
routine check-up and it is a common finding among 
Romanian patients, some studies reporting a prevalence 
>65% (7).  
Thus, our objective was to evaluate cardio metabolic 
risk factors for AF in T2DM patients, particularly 
focusing on the metabolic syndrome, hypertension and 
obesity. 
Materials and Methods 
Study design 
A cross-sectional observational retrospective study 
was conducted to evaluate cardio metabolic risk factors 
for AF in patients diagnosed with T2DM. 
Setting 
The study was conducted from January to June 2018 
in the Internal Medicine Clinic of a tertiary care teaching 
center located in Bucharest, Romania. 
Participants 
A total of 221 patients were included in the study, 
representing all patients diagnosed with T2DM who were 
referred to the Internal Medicine Clinic from January to 
June 2018. 
Data sources and variables 
The data were collected by utilizing electronic medical 
records of patients diagnosed with T2DM. The 
information obtained from the medical records was 
collected by means of a structured form that included: 
age, sex, comorbidities and treatment. 
Bias 
To reduce selection bias, we included all patients 
diagnosed with T2DM in the time period of the study. 
Patients with incomplete medical records were excluded. 
Statistical methods 
Categorical variables were presented as frequencies 
and percentages. Continuous variables were presented as 
the mean ± SD. Patients were divided according to the 
presence and absence of AF, metabolic syndrome, obesity 
and hypertension. Categorical variables were compared 
using Fisher’s exact test.  
Continuous variables were compared using 
independent t-test samples. The level of significance was 
presented as p-values in different tables. The analysis was 
performed at a 5% level of significance using Microsoft 
Excel (Microsoft Office Professional Plus 2013), 
MedCalc (https://www.medcalc.org) and GraphPad 
QuickCalcs (https://www.graphpad.com). 
Ethical standards 
The study was conducted in accordance with the 
national law and the Declaration of Helsinki (1975), as 
revised in 2008 (5). All patients signed an informed 
consent upon admission, agreeing to have their medical 
records reviewed for scientific purposes as long as their 
confidentiality is respected. 
Results 
The study group included 221 patients diagnosed with 
T2DM (with a mean age of 68.65 ± 10.64, ranging 
between 37-93 years): 116 women (52.49%; with a mean 
age of 70.53 ± 10.69, ranging between 37-93 years) and 
105 men (47.51%; with a mean age of 66.57 ± 10.23, 
ranging between 38-91 years). 92 patients had AF 
(41.63%): 40 women (34.48%) and 52 men (49.52%). 180 
patients (81.45%) were hypertensive: 103 women 
(88.79%) and 77 men (73.33%). 113 patients (51.13%) 
had metabolic syndrome: 58 women (50.00%) and 55 
men (52.38%). 77 patients (34.84%) were obese: 45 
women (38.79%) and 32 men (30.48%). These results are 
presented in Table 1. 
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Table 1. The characteristics of patients included 
in the study 
 Women Men p-value 
Age 
70.53 ± 10.69 
years 
66.57 ± 10.23 
years 
0.0080 
Number 116 (52.49%) 105 (47.51%) - 
Atrial 
fibrillation 
Yes 
40 
(34.48%) 
Yes 
52 
(49.52%) 
0.0288 
No 
76 
(65.52%) 
No 
53 
(50.48%) 
Hypertension 
Yes 
103 
(88.79%) 
Yes 
77 
(73.33%) 
0.0051 
No 
13 
(11.21%) 
No 
28 
(26.67%) 
Metabolic 
syndrome 
Yes 
58 
(50.00%) 
Yes 
55 
(52.38%) 
0.7879 
No 
58 
(50.00%) 
No 
50 
(47.62%) 
Obesity 
Yes 
45 
(38.79%) 
Yes 
32 
(30.48%) 
0.2063 
No 
71 
(61.21%) 
No 
73 
(69.52%) 
AF patients associated obesity in 26 cases (28.26%), 
hypertension in 73 cases (79.35%) and the metabolic 
syndrome in 56 cases (60.87%), as seen in Table 2 (OR = 
odds ratio, CI = confidence intervals). 
Discussions 
In the current study, 221 patients with T2DM were 
recruited over a period of six months based on the 
medical records of the Internal Medicine Clinic of a 
referral emergency hospital in Bucharest, Romania. Out 
of this group, 92 patients (41.63%) had also been 
diagnosed with AF, men being more likely to suffer from 
AF than women (p=0.0288), as similar studies have 
previously reported (8, 9). Hypertension affected 180 
patients (81.45%), women in a greater proportion than 
men (p=0.0051). The metabolic syndrome and obesity 
were discovered in 113 (51.13%) and 77 patients 
(34.84%), respectively, with no significant differences in 
terms of gender. In our research, the highest cardio 
metabolic risk factors for AF in T2DM were hypertension 
(OR = 3.6675) and the metabolic syndrome (OR = 
3.3388). 
The management of both type 1 and type 2 diabetes 
mellitus will still remain a challenge, even in the near 
future: the prevalence of diabetes in the United States is 
rapidly growing, with reports estimating that by 2030 
more than 54.9 million people will suffer from diagnosed 
or undiagnosed diabetes, as opposed to approximately 
35.6 million people in 2015 (10). As compared to the 
general population, patients diagnosed with T2DM are 
more likely to suffer from AF as well: Zethelius et al. 
investigated which are the risk factors for AF in T2DM 
and concluded that there was a strong association between 
obesity/body mass index, hypertension and albuminuria 
and AF in T2DM (11). 
The pathophysiology of AF in T2DM is complex. 
Hyperglycemia and hypertension are key players in the 
development of AF in patients with diabetes: 
hyperglycemia leads to increased levels of inflammatory 
markers, reactive oxygen species and advanced 
glycosylation end products at a myocardial level, 
promoting atrial fibrosis, whereas hypertension promotes 
atrial dilatation (12). Atrial dilatation is also enhanced by 
the proliferation of atrial fibroblasts. Both conditions lead 
to structural and electrical remodeling of the left atrium 
and explain the development of AF in T2DM (1, 13, 14). 
The contribution of oxidative stress might also be 
determined by additional exposure to exogenous sources 
of ROS, as well as the reduced capacity of antioxidant 
defense systems to scavenge these molecules in the 
elderly since their efficiency is age-dependent (15,16). 
Irrespective of its relationship with T2DM, AF should 
be appropriately managed. Therapeutic solutions include 
either rate control or rhythm control options and, in 
patients with CHA2DS2-VASc score of at least one point, 
anticoagulation agents should be prescribed to prevent 
thromboembolism and cardiovascular mortality (1, 17- 
19).
 
Table 2. Cardio metabolic risk factors for AF in T2DM 
 AF + AF - OR 95% CI p-value 
Hypertension 
Yes 73 (79.35%) Yes 66 (51.16%) 
3.6675 1.99-6.76 <0.0001 
No 19 (20.65%) No 63 (48.84%) 
Metabolic syndrome 
Yes 56 (60.87%) Yes 41 (31.78%) 
3.3388 1.91-5.84 <0.0001 
No 36 (39.13%) No 88 (68.22%) 
Obesity 
Yes 26 (28.26%) Yes 23 (17.83%) 
1.8155 0.96-3.44 0.0677 
No 66 (71.74%) No 106 (82.17%) 
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Conclusions 
Cardio metabolic risk factors for AF (hypertension, 
metabolic syndrome and obesity) were found in a 
substantial percentage in the study group. Women were 
more likely to be hypertensive than men. There were no 
statistically significant differences between genders 
regarding the metabolic syndrome or obesity. In the study 
group, 41.63% of the patients diagnosed with T2DM also 
associated AF. Diabetic men were more likely to have AF 
than women. AF was strongly associated with 
hypertension and metabolic syndrome in diabetic patients. 
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